{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(16)"],"submitter":["Pantanetti P"],"pubmed_abstract":["<b>Background</b>: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of incretin mimetics for treating type 2 diabetes (T2D). This study evaluated the impact of semaglutide, the first oral GLP-1RA, on glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and body composition and anthropometric parameters. Additionally, the effects on cardiovascular risk factors and quality of life (QoL) in T2D patients were assessed. <b>Methods</b>: A prospective observational study with a six-month follow-up was conducted. Clinical parameters, including HbA1c, FPG, anthropometric measurements, blood pressure, cardiovascular risk factors, Diabetes Treatment Satisfaction Questionnaire (DTSQ) responses, and Short Form (36) Health Survey (SF-36) responses, were collected at baseline"],"journal":["Journal of clinical medicine"],"pagination":["4752"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11355440"],"repository":["biostudies-literature"],"pubmed_title":["Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice."],"pmcid":["PMC11355440"],"pubmed_authors":["Mancin S","Tartaglia FC","Petrelli F","Ronconi V","Sguanci M","Pantanetti P","Cangelosi G","Palomares SM"],"additional_accession":[]},"is_claimable":false,"name":"Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.","description":"<b>Background</b>: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a novel class of incretin mimetics for treating type 2 diabetes (T2D). This study evaluated the impact of semaglutide, the first oral GLP-1RA, on glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and body composition and anthropometric parameters. Additionally, the effects on cardiovascular risk factors and quality of life (QoL) in T2D patients were assessed. <b>Methods</b>: A prospective observational study with a six-month follow-up was conducted. Clinical parameters, including HbA1c, FPG, anthropometric measurements, blood pressure, cardiovascular risk factors, Diabetes Treatment Satisfaction Questionnaire (DTSQ) responses, and Short Form (36) Health Survey (SF-36) responses, were collected at baseline","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2025-04-05T12:30:46.849Z","creation":"2025-04-05T12:30:46.849Z"},"accession":"S-EPMC11355440","cross_references":{"pubmed":["39200893"],"doi":["10.3390/jcm13164752"]}}